Aster DM Quality Care has acquired a 14.21% equity stake in Bangladesh-based STS Holdings Limited through its Mauritius subsidiary, Chemistry Intermediate Holdings Limited. The transaction, valued at USD 44,114,339, aligns with the Merger Framework Agreement executed on November 29, 2024.

The acquisition involves the purchase of 22,727,584 equity shares at a price equivalent to BDT 273.45 per share. Each share carries a face value of BDT 10. The investment is structured as a cash consideration and does not fall under related-party transactions, with no promoter or group company interest in the target entity.

Transaction Details

The deal follows the approval of the Scheme of Amalgamation between Quality Care India Limited and Aster DM Healthcare Limited by the National Company Law Tribunal, Hyderabad Bench, on June 19, 2026. No further governmental or regulatory approvals are required for this specific acquisition.

What the Numbers Show

STS Holdings Limited operates in the healthcare services and training sector in Bangladesh. The company has demonstrated consistent top-line expansion over the past three fiscal years.

The turnover grew from BDT 7,777.02 million in FY24 to BDT 10,534.24 million in FY26, reflecting a sustained upward trajectory in the target’s revenue base prior to this acquisition.

Aster DM Quality Care Limited has issued a postal ballot notice seeking shareholder approval for key governance changes, including the appointment of a new Managing Director and Group CEO. The vote will also cover remuneration revisions for existing leadership and the adoption of a fresh employee stock option plan.

The remote e-voting process commences on August 27, 2026, and concludes on September 25, 2026. The proposals align with the governance framework established under the Shareholders' Agreement following the company's amalgamation with Quality Care India Limited.

Leadership Appointments

The notice proposes the appointment of Mr. Varun Shadilal Khanna as Managing Director and Group Chief Executive Officer for a five-year term starting July 1, 2026. His consolidated remuneration includes fixed pay of ₹8.10 crore per annum and performance-linked variable pay of ₹3.15 crore per annum at target levels.

Additionally, the company seeks approval for the appointment of three Non-Executive Independent Directors: Mr. Neeraj Jain, Mr. Kewal Kundanlal Handa, and Mr. Valayil Korath Mathews. Each will serve a three-year term ending June 30, 2029, with remuneration capped at ₹40 lakh per annum.

Two Non-Executive Non-Independent Directors are also proposed: Ms. Ayshwarya Ravi Vikram and Mr. Ganesh Mani, both effective from July 1, 2026.

Remuneration Revisions

Shareholder consent is sought to revise the managerial remuneration of Dr. Mandayapurath Azad Moopen, Executive Chairman. His consolidated remuneration is proposed at up to ₹12.25 crore per annum for the period from July 1, 2026, to May 28, 2028.

The notice also proposes redesignating Ms. Alisha Moopen from Deputy Managing Director to Executive Director. Her revised remuneration is capped at ₹2.00 crore per annum until August 6, 2029.

Employee Stock Option Scheme

The company proposes the Aster DM Quality Care Limited Employee Stock Option Scheme – 2026. The scheme authorizes the grant of 1,52,54,268 equity shares to eligible employees. This represents approximately 1.75% of the paid-up share capital post-merger.

An additional pool of 76,27,134 options is reserved for employees of unlisted subsidiary companies. The initial exercise price for options granted within 90 days of the scheme's adoption is set at ₹319.40 per share, reflecting a 30% discount to the merger share swap ratio value of ₹456.33.

What the Numbers Show

The proposed ESOP pool size of 1.75% positions Aster DM Quality Care competitively within the healthcare sector. Peer benchmarking data provided in the notice indicates that Max Healthcare Institute Limited maintains an ESOP pool of 4.28%, Fortis Healthcare Limited holds 1.91%, and Apollo Hospitals Enterprise Limited retains 1.50%. The new scheme aims to align employee incentives with long-term value creation following the integration of the merged entity.